Dolutegravir plus tenofovir alafenamide as a double-drug regimen in HIV positive patients
Phase 3
Recruiting
- Conditions
- Virologically Undetectable HIV Patients.
- Registration Number
- IRCT20191005044984N1
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Adults older than 18 years old
HIV positive patients with undetectable viral load for at least 2 years
HIV positive patients with CD4 cells count >200 for at least 2 years
Patients who are on first line antiretroviral therapy for at least 2 years
No any mutation against INSTI or NRTI drugs
Adequate adherence to treatment
No any AIDS-related event (opportunistic infection or cancer)
Exclusion Criteria
Pregnancy and lactation
Concomitant viral co-infections including hepatitis B or C
Existing any co-morbidity that requiring treatment which may have significant interactions with ART
Renal or hepatic diseases
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method